CD19 and neoplasm: In addition to their anti-tumor activity, γδT cells transduced with a CD19-specific CAR are less prone to exhaustion (178), suggesting that the use of CAR γδT cells may reduce concerns about T cell exhaustion in patients and result in a more long-lived anti-tumor response.